Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 1998

View Archived Issues

DNA immunization against rabies effectively protects nonhuman primates

Alpha-Beta Technology: Q2 1998 highlights

Orion: six-month highlights

Late-stage clinical trials of Oralin to begin in Canada

Canadian launch for minimally invasive impotence treatment

Phase II trial commences of AG-3340 in AMD

Inhibitors of telomerase focus of investigation at CRC Technology, U. Texas

Japanese and Dutch scientists design LTD4 and dual LTD4/H1 antagonists

Amersham Pharmacia Biotech completes tender offer for Molecular Dynamics

Selective 5-HT2C antagonist selected for development at Organon

SuperGen expands phase III trials of RFS-2000 in pancreatic cancer

Russian scientists identify GABA analogue with hypotensive activity

Astra Arcus develops first full, selective alpha7 nAChR agonist

Glaxo Wellcome studies lamotrigine analogues in the search for new anticonvulsants

Organon discovers new pharmacophore providing potent, orally active thrombin inhibitors

Novo files for U.S. marketing approval of insulin analogue

First group 1 mGluR antagonist with submicromolar potency described by Lilly

GW-273227, a sodium channel blocker for the treatment of pain

Advisory committee unanimously recommends approval for Enbrel

Nasal calcitonin reduces spinal fractures in postmenopausal women with osteoporosis

Medical device for rheumatoid arthritis scheduled for October advisory panel review

New treatment for BPH discovered by Hungarian research team

Famciclovir effectively suppresses recurrent genital herpes

Baxter refocuses blood substitute program

IND filed for new insomnia drug candidate from Neurogen and Pfizer

Neurogen epilepsy drug candidate undergoes further preclinical trials

La Jolla identifies target of antibodies responsible for life-threatening autoimmune disorder

Sanofi/BMS antiplatelet agent introduced in U.K.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...